1 – 20 of 71
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
The basal forebrain cholinergic system as target for cell replacement therapy in Parkinson's disease
(
- Contribution to journal › Scientific review
-
Mark
The history and status of dopamine cell therapies for Parkinson's disease
2024) In BioEssays(
- Contribution to journal › Scientific review
-
Mark
The AAV-α-Synuclein Model of Parkinson's Disease : An Update
2024) In Journal of Parkinson's Disease(
- Contribution to journal › Scientific review
- 2023
-
Mark
Preclinical quality, safety, and efficacy of a human embryonic stem cell-derived product for the treatment of Parkinson's disease, STEM-PD
(
- Contribution to journal › Article
- 2021
-
Mark
Dopamine Cell Therapy : From Cell Replacement to Circuitry Repair
(
- Contribution to journal › Scientific review
- 2020
-
Mark
From Skin to Brain : A Parkinson's Disease Patient Transplanted with His Own Cells
(
- Contribution to journal › Article
-
Mark
GDNF and Parkinson's Disease : Where Next? A Summary from a Recent Workshop
(
- Contribution to journal › Article
-
Mark
Preface : The evolving scenario of Parkinson's research
(
- Chapter in Book/Report/Conference proceeding › Foreword/Postscript
- 2017
-
Mark
Replacing Dopamine Neurons in Parkinson's Disease : How did it happen?
(
- Contribution to journal › Scientific review
- 2016
-
Mark
Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain.
2016) In Proceedings of the National Academy of Sciences of the United States of America 113(23). p.6544-6549(
- Contribution to journal › Article
-
Mark
Emotional memory impairments induced by AAV-mediated overexpression of human α-synuclein in dopaminergic neurons of the ventral tegmental area.
(
- Contribution to journal › Article
- 2015
-
Mark
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
(
- Contribution to journal › Article
- 2014
-
Mark
Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
(
- Contribution to journal › Article
-
Mark
Long-term clinical outcome of fetal cell transplantation for Parkinson disease : two case reports
(
- Contribution to journal › Article
- 2013
-
Mark
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia
(
- Contribution to journal › Article
-
Mark
mTOR Inhibition Alleviates L-DOPA-Induced Dyskinesia in Parkinsonian Rats
(
- Contribution to journal › Article
-
Mark
NURR1 in Parkinson disease-from pathogenesis to therapeutic potential.
(
- Contribution to journal › Scientific review
-
Mark
Trophic Factor Gene Therapy for Parkinson's Disease
(
- Contribution to journal › Scientific review
-
Mark
Cell therapy for Parkinson's disease: what next?
(
- Contribution to journal › Article
-
Mark
Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease
(
- Contribution to journal › Scientific review